The ufmylation modification of ribosomal protein L10 in the development of pancreatic adenocarcinoma.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
07 06 2023
07 06 2023
Historique:
received:
13
12
2022
accepted:
31
05
2023
revised:
04
05
2023
medline:
8
6
2023
pubmed:
7
6
2023
entrez:
6
6
2023
Statut:
epublish
Résumé
Pancreatic adenocarcinoma (PAAD) is the most malignant cancer with a high mortality rate. Despite the association of ribosomal protein L10 (RPL10) with PAAD and previous reports on RPL26 ufmylation, the relationship between RPL10 ufmylation and PAAD development remains unexplored. Here, we report the dissection of ufmylating process of RPL10 and potential roles of RPL10 ufmylation in PAAD development. The ufmylation of RPL10 was confirmed in both pancreatic patient tissues and cell lines, and specific modification sites were identified and verified. Phenotypically, RPL10 ufmylation significantly increased cell proliferation and stemness, which is principally resulted from higher expression of transcription factor KLF4. Moreover, the mutagenesis of ufmylation sites in RPL10 further demonstrated the connection of RPL10 ufmylation with cell proliferation and stemness. Collectively, this study reveals that PRL10 ufmylation plays an important role to enhance the stemness of pancreatic cancer cells for PAAD development.
Identifiants
pubmed: 37280198
doi: 10.1038/s41419-023-05877-y
pii: 10.1038/s41419-023-05877-y
pmc: PMC10244432
doi:
Substances chimiques
Ribosomal Proteins
0
RPL10 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
350Informations de copyright
© 2023. The Author(s).
Références
Cancer Res. 2019 Jan 15;79(2):320-327
pubmed: 30482776
FEBS Lett. 2017 Jan;591(1):196-204
pubmed: 27926783
Clin Cancer Res. 2008 Mar 1;14(5):1284-5
pubmed: 18316544
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Carcinogenesis. 2002 Jun;23(6):967-75
pubmed: 12082018
Cancers (Basel). 2018 Nov 28;10(12):
pubmed: 30486519
EMBO J. 2022 Nov 2;41(21):e111015
pubmed: 36121123
Cell Res. 2020 Jan;30(1):5-20
pubmed: 31595041
Trends Cell Biol. 2019 Dec;29(12):974-986
pubmed: 31703843
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Cell Biol. 2020 Sep;22(9):1056-1063
pubmed: 32807901
Cell Rep. 2022 Aug 2;40(5):111168
pubmed: 35926457
Cancer Res. 2021 Jan 1;81(1):91-102
pubmed: 33127746
Cell. 2001 Nov 2;107(3):373-86
pubmed: 11701127
Mol Cell Biol. 2005 May;25(9):3802-13
pubmed: 15831484
Nucleic Acids Res. 2019 May 7;47(8):4124-4135
pubmed: 30783677
Cell. 2017 Jun 1;169(6):1051-1065.e18
pubmed: 28575669
Leukemia. 2018 Mar;32(3):809-819
pubmed: 28744013
Cell Rep. 2016 Jul 12;16(2):288-294
pubmed: 27373148
Mol Cell. 2014 Oct 23;56(2):261-274
pubmed: 25219498
Cancer Epidemiol. 2019 Feb;58:104-110
pubmed: 30537645
Mol Cancer. 2015 Oct 12;14:179
pubmed: 26458814
Nat Genet. 2013 Feb;45(2):186-90
pubmed: 23263491
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1299-1308
pubmed: 30626644
Cancer Biol Ther. 2006 May;5(5):523-8
pubmed: 16627977
Redox Biol. 2018 Oct;19:158-165
pubmed: 30172100
Prostate Cancer Prostatic Dis. 2006;9(1):77-82
pubmed: 16331298
J Biol Chem. 2007 Feb 23;282(8):5256-62
pubmed: 17182609
Int J Mol Sci. 2011;12(3):1595-604
pubmed: 21673909
FEMS Yeast Res. 2004 Dec;5(3):271-80
pubmed: 15556089
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348
pubmed: 29717230
Asian Pac J Cancer Prev. 2020 Aug 01;21(8):2271-2280
pubmed: 32856855
Stem Cell Res Ther. 2015 Sep 22;6:182
pubmed: 26395574
Annu Rev Biochem. 2015;84:93-129
pubmed: 25706898
Oncotarget. 2017 May 23;8(21):35009-35018
pubmed: 28388532
ACS Chem Biol. 2017 Apr 21;12(4):899-904
pubmed: 28186401
Nucleic Acids Res. 1991 Oct 25;19(20):5763-9
pubmed: 1658743
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Cells. 2020 Nov 19;9(11):
pubmed: 33227977
Blood. 1992 Nov 1;80(9):2230-6
pubmed: 1384798
J Cancer. 2018 Feb 6;9(4):745-756
pubmed: 29556332